Literature DB >> 19829149

Molecular monitoring of 8p11 myeloproliferative syndrome in an infant.

Wenyong W Zhang1, Sultan Habeebu, Andrea M Sheehan, Rizwan Naeem, Vivian S Hernandez, Zoann E Dreyer, Dolores López-Terrada.   

Abstract

The 8p11 myeloproliferative syndrome is a rare hematologic malignancy derived from a pluripotent hematopoietic stem cell associated with rearrangements involving the fibroblast growth factor receptor 1 (FGFR1) gene located on chromosome 8p11. The most common translocation, t(8;13) (p11;q13), results in a ZNF198-FGFR1 fusion gene and constitutively active FGFR1 tyrosine kinase activity. Typical pathologic findings include myeloid hyperplasia, lymphadenopathy, precursor T-lymphoblastic lymphoma, and eosinophilia. The disease is usually associated with an aggressive course and progression to acute myeloid leukemia is frequent. We report here the first case of 8p11 myeloproliferative syndrome in an infant and demonstrate the value of molecular testing in the diagnosis and minimal disease monitoring of this rare disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19829149     DOI: 10.1097/MPH.0b013e3181b83fd0

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.

Authors:  Michael Zinke; Vanasa Nageswaran; Richard Reinhardt; Thomas Burmeister
Journal:  Mol Diagn Ther       Date:  2015-10       Impact factor: 4.074

2.  Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.

Authors:  MingQiang Ren; John K Cowell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

Review 3.  [Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review].

Authors:  Y T Liu; J W Zhao; J Feng; Q H Li; Y M Chen; L G Qiu; Z J Xiao; Y Li; B F Gong; X Y Gong; Y C Mi; J X Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-10-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.